Abbott Expects Science To “Trump” Scale; Sees Industry In “Transformation”
Executive Summary
Abbott's formula for navigating a period of "transformation" in the pharmaceutical industry includes focusing on therapeutic categories where science matters more than scale, CEO Miles White told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 3 in New York